Operational performance of a new molecular-based point-of-care test for diagnosis of <em>Chlamydia trachomatis </em>and <em>Neisseria gonorrhoeae</em> infection: concordance with conventional laboratory testing — ASN Events
  1. Schedule
  2. Public health microbiology
  3. Public Health Microbiology
  4. Operational performance of a new molecular-based point-of-care test for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection: concordance with conventional laboratory testing

Operational performance of a new molecular-based point-of-care test for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection: concordance with conventional laboratory testing (#143)

Louise M Causer 1 , Annie Tangey 2 , Steven G Badman 1 , Belinda Hengel 3 , Lisa Natoli 4 , David Speers 5 , Sepehr N Tabrizi 6 , David Whiley 7 , David A Anderson 4 , James Ward 8 , John M Kaldor 1 , Rebecca J Guy 1 , on behalf of the TTANGO investigators
  1. Kirby Institute, UNSW, Sydney, NSW, Australia
  2. Ngaanyatjarra Health Service, Warburton, WA, Australia
  3. Apunipima Cape York Health Council, Cairns, Qld, Australia
  4. The Burnet Institute, Melbourne, Vic, Australia
  5. Department of Microbiology, PathWest Laboratory Medicine, Nedlands, WA, Australia
  6. The Royal Women’s Hospital and Murdoch Childrens Research Institute, Parkville, Vic, Australia
  7. Queensland Paediatric Infectious Diseases (QPID) Laboratory, Brisbane, Qld, Australia
  8. South Australian Health and Medical Research Institute, Adelaide, SA, Australia

Background

New molecular-based point-of-care(POC) tests for Chlamydia trachomatis(CT) and Neisseria gonorrhoeae(NG) infections are being used for the first time by trained Aboriginal health workers/practitioners, registered/enrolled nurses and medical officers in regional and remote health services in Australia as part of the TTANGO (Test, Treat ANd GO) trial. We assessed the operational performance of the GeneXpert®CT/NG assay (Cepheid) POC test at these services using conventional laboratory tests as the reference standard.

Methods

TTANGO, a randomised cross-over control trial of CT/NG POC testing, commenced June 2013. To date, 12 services have implemented GeneXpert testing on-site as routine practice, with specimens continuing to be sent to jurisdictional laboratories for conventional nucleic acid amplification testing (NAAT) as usual. We assessed the concordance of GeneXpert performed by health service staff with conventional laboratory NAAT. We also present selected details of discordant specimens.

Results

Among 1995 GeneXpert tests performed, CT and NG were detected in 182 and 127, respectively, by the jurisdictional laboratory. Concordance for CT was 99.4% (95% CI: 99.0 – 99.8) and NG was 99.9% (99.6-100.0).  The fourteen discordant results (eight urines, six lower vaginal swabs) were identified in seven services and five laboratories (two use Cobas 4800, three use Aptima). Discordant results were predominantly CT(n=12) and most(n=10) were positive POC/negative laboratory results. The median POC test crossing point among CT discordants was 37.2(IQR:31.6-37.7) with five of nine(55.6%) having crossing points>35, compared to 29.2(IQR:26.3-32.6) among CT concordants with 10 of 179(5.5%) having crossing points>35. The two NG discordant results were both positive POC/negative laboratory results.

Conclusion

The performance of GeneXpert CT/NG in the hands of trained health service staff is excellent and consistent with previous laboratory and field evaluations. Higher crossing points of discordant results most likely indicates low organism loads close to test detection threshold and seem unrelated to service, laboratory, specimen type or reference assay. Overall, results show the GeneXpert method is suitable for routine detection of CT and NG.

#2015ASM